Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

"Bavituximab" ... its MOA is being tried by

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biopharm Member Profile
Member Level 
Followed By 83
Posts 13,254
Boards Moderated 1
Alias Born 10/12/10
160x600 placeholder
Illumina, Roche Enter Partnership to Use Genomics for Medical Diagnosis Dow Jones News - 1/13/2020 1:14:00 PM
Bristol-Myers Squibb, Macy's, Grubhub: Stocks That Defined the Week Dow Jones News - 1/10/2020 6:33:00 PM
Sarepta Shares Gain After Licensing Deal With Roche Dow Jones News - 12/23/2019 7:48:00 AM
Drugmakers Turn to Data Mining to Avoid Expensive, Lengthy Drug Trials Dow Jones News - 12/23/2019 5:59:00 AM
Sensyne Health Signs AI Research Pact With Roche Dow Jones News - 12/23/2019 5:31:00 AM
Roche Enters Licensing Agreement With Sarepta Therapeutics for Gene Therapy Dow Jones News - 12/23/2019 2:25:00 AM
Genentech: Tecentriq/Cotellic/Zelboraf Combo Study Meets Primary Endpoint Dow Jones News - 12/13/2019 7:37:00 AM
Genentech: Subcutaneous Perjeta/Herceptin Combo Comparable to IV Dow Jones News - 12/12/2019 11:44:00 AM
Novartis: FDA Accepts Xolair sBLA for Nasal Polyps Dow Jones News - 12/11/2019 6:37:00 AM
Roche Approves Proposals for Board and Executive Committee Dow Jones News - 12/9/2019 2:50:00 AM
Roche Extends Tender Offer for Spark Therapeutics Dow Jones News - 12/9/2019 2:16:00 AM
FDA Approves Marketing of Roche Diagnostics MRSA Diagnostic Test Dow Jones News - 12/5/2019 1:10:00 PM
Genentech: FDA Approves Tecentriq Plus Chemotherapy for Some Non-Small Cell Lung Cancer Dow Jones News - 12/3/2019 7:21:00 PM
Genentech Gets FDA Priority Review for Risdiplam for Spinal Muscular Atrophy Dow Jones News - 11/25/2019 7:36:00 AM
FDA Accepts Avastin Biosimilar BLA From Biogen, Samsung BioLogics Venture Dow Jones News - 11/19/2019 8:45:00 AM
New Hope in the Battle Against Ovarian Cancer NetworkNewsWire - 11/5/2019 8:45:00 AM
Delivering Precision Medicine’s True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics NetworkNewsWire - 10/29/2019 8:45:00 AM
U.K.'s Competition Watchdog Opens Probe into Roche Takeover of Spark Therapeutics Dow Jones News - 10/22/2019 2:46:00 AM
Roche: Phase 3 Study of Tecentriq, Avastin Combination a Success Dow Jones News - 10/21/2019 1:44:00 AM
Roche Says Outlook Is Improving as Revenue Grows Dow Jones News - 10/16/2019 1:48:00 AM
Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive Dow Jones News - 9/30/2019 11:20:00 AM
Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders Dow Jones News - 9/27/2019 2:32:00 PM
Genentech Says Data Positive From Tecentriq Lung Cancer Study Dow Jones News - 9/27/2019 11:20:00 AM
U.K. Regulator to Probe Roche's Acquisition of Spark Therapeutics Dow Jones News - 9/25/2019 2:54:00 AM
Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers NetworkNewsWire - 9/24/2019 8:45:00 AM
biopharm Member Level  Saturday, 06/08/13 12:30:54 PM
Re: Princessbarbie post# 97
Post # of 138 
"Bavituximab" ... its MOA is being tried by others by Peregrine has the patent locked up for the upper up stream target of Phosphatidylserine (PS). No other Big Pharma can target it... and when you target PS which is outside the cell cembrane, the result is less side affects. No toxic side affects.

Peregrine just went to ASCO 2013 with a Phase III pre-approval for their NSCLC phase IIb trial so we know where the FDA stands if they approved this before ASCO 2013. Peregrine/Genetech/Roche... wow, just imagine that : ) If Avastin has the side affects and replaced by Bavi... Avastin/Roche will be more like it.


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist